Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 188

Similar articles for PubMed (Select 10817549)

2.
3.

A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group.

Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, Helgetveit KB, Kress B, Daniels B, Bolognese J, Krupa D, Seidenberg B, Ehrich E.

Arch Intern Med. 2000 Jun 26;160(12):1781-7.

PMID:
10871971
4.

A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis.

Zacher J, Feldman D, Gerli R, Scott D, Hou SM, Uebelhart D, Rodger IW, Ozturk ZE; etoricoxib OA study group.

Curr Med Res Opin. 2003;19(8):725-36. Erratum in: Curr Med Res Opin. 2004 Oct;20(10):1689.

PMID:
14687444
5.
6.

Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.

Ehrich EW, Schnitzer TJ, McIlwain H, Levy R, Wolfe F, Weisman M, Zeng Q, Morrison B, Bolognese J, Seidenberg B, Gertz BJ.

J Rheumatol. 1999 Nov;26(11):2438-47.

PMID:
10555907
8.

Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial.

Kivitz AJ, Greenwald MW, Cohen SB, Polis AB, Najarian DK, Dixon ME, Moidel RA, Green JA, Baraf HS, Petruschke RA, Matsumoto AK, Geba GP; Protocol 085 Study Investigators.

J Am Geriatr Soc. 2004 May;52(5):666-74.

PMID:
15086644
9.
10.

Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.

Gottesdiener K, Schnitzer T, Fisher C, Bockow B, Markenson J, Ko A, DeTora L, Curtis S, Geissler L, Gertz BJ; Protocol 007 Study Group.

Rheumatology (Oxford). 2002 Sep;41(9):1052-61. Erratum in: Rheumatology (Oxford). 2003 Jun;42(6):814.

13.
14.
15.

Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.

Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, Dixon ME, Polis AB, Mollen AJ, Geba GP; ADVANTAGE Study Group.

Ann Intern Med. 2003 Oct 7;139(7):539-46.

PMID:
14530224
16.

Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial.

Schnitzer TJ, Beier J, Geusens P, Hasler P, Patel SK, Senftleber I, Gitton X, Moore A, Sloan VS, Poór G.

Arthritis Rheum. 2004 Aug 15;51(4):549-57.

17.
18.
20.

Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial.

Leung AT, Malmstrom K, Gallacher AE, Sarembock B, Poor G, Beaulieu A, Castro R, Sanchez M, Detora LM, Ng J.

Curr Med Res Opin. 2002;18(2):49-58.

PMID:
12017209
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk